Proteomic Analysis of Cerebrospinal Fluid from Obese Women with Idiopathic Intracranial Hypertension: A New Approach for Identifying New Candidates in the Pathogenesis of Obesity

Journal of Neuroendocrinology

Volumn 24, Issue 6, 2012, Pages 944-952

  Lecube, A ^a   Poca, M A ^b   Colome N ^c   Bech Serra, J J ^c   Hernandez C ^a   Garcia Ramirez M ^a   Gandara D ^b   Canals, F ^c   Simo R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

Cerebrospinal fluid; Obesity; Proteomic analysis

Indexed keywords

CHROMOGRANIN A; CHROMOGRANIN B; FIBRINOGEN; FIBRONECTIN; GALECTIN 3; GLYCOPROTEIN; HAPTOGLOBIN; ISOTOPE; METALLOTHIONEIN I; METALLOTHIONEIN III; OSTEOPONTIN;

ADULT; ARTICLE; BETA CHAIN; BLOOD SAMPLING; CASE CONTROL STUDY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IDIOPATHIC INTRACRANIAL HYPERTENSION; INFLAMMATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NERVE CELL PLASTICITY; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; VENTRICULOATRIAL SHUNT; WESTERN BLOTTING;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; PROTEOMICS; PSEUDOTUMOR CEREBRI;

EID: 84860898810     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2012.02288.x     Document Type: Article

References (40)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
2. Beck B. Neuropeptides and obesity. Nutrition 2000; 16: 916-923.
3. Williams G, Bing C, Cai XJ, Harrold JA, King PJ, Liu XH. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 2001; 74: 683-701.
4. Kos K, Harte AL, da Silva NF, Tonchev A, Chaldakov G, James S, Snead DR, Hoggart B, O'Hare JP, McTernan PG, Kumar S. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab 2007; 92: 1129-1136.
5. Ball AK, Sinclair AJ, Curnow SJ, Tomlinson JW, Burdon MA, Walker EA, Stewart PM, Nightingale PG, Clarke CE, Rauz S. Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance? Clin Endocrinol (Oxf) 2009; 70: 863-869.
6. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007; 61: 120-129.
7. Huang JT, Leweke FM, Tsang TM, Koethe D, Kranaster L, Gerth CW, Gross S, Schreiber D, Ruhrmann S, Schultze-Lutter F, Klosterkötter J, Holmes E, Bahn S. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2007; 2: e756.
8. Xiao F, Chen D, Lu Y, Xiao Z, Guan LF, Yuan J, Wang L, Xi ZQ, Wang XF. Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy. Brain Res 2009; 1255: 180-189.
9. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59: 1492-1495.
10. Schmidt A, Kellermann J, Lottspeich F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 2005; 5: 4-15.
11. Poca MA, Martínez-Ricarte F, Sahuquillo J, Lastra R, Torné R, Armengol MS. Intracranial pressure monitoring with the Neurodur-P epidural sensor: a prospective study in patients with adult hydrocephalus or idiopathic intracranial hypertension. J Neurosurg 2008; 108: 934-942.
12. Colomé N, Collado J, Bech-Serra JJ, Liiv I, Antón LC, Peterson P, Canals F, Jaraquemada D, Alvarez I. Increased apoptosis after autoimmune regulator expression in epithelial cells revealed by a combined quantitative proteomics approach. J Proteome Res 2010; 9: 2600-2609.
13. Kersey PJ, Duarte J, Williams A, Karavidopoulou Y, Birney E, Apweiler R. The International Protein Index: an integrated database for proteomics experiments. Proteomics 2004; 4: 1985-1988.
14. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998; 152: 353-358.
15. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodelating, and cell survival. J Clin Invest 2001; 107: 1055-1061.
16. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL, Kawamori R, Cassis LA, Tschöp MH, Bruemmer D. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 2007; 117: 2877-2888.
17. Gomez-Ambrosi J, Catalan V, Ramírez B, Rodríguez A, Colina I, Silva C, Rotellar F, Mugueta C, Gil MJ, Cienfuegos JA, Salvador J, Frühbeck G. Plasma osteopontin levels and expresión in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007; 92: 3719-3727.
18. Nguyen XM, Lane J, Smith BR, Nguyen NT. Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. J Gastrointest Surg 2009; 13: 1205-1212.
19. Milanski M, Degasperi G, Coope A, Morati J, Denis R, Cintra DE, Tsukumo DM, Anhe G, Amaral ME, Takahashi HK, Curi R, Oliveira HC, Carvalheira JB, Bordin S, Saad MJ, Velloso LA. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J Neurosci 2009; 29: 359-370.
20. Thaler JP, Choi SJ, Schwartz MW, Wise BE. Hypothalamic inflammation and energy homeostasis: resolving the paradox. Front Neuroendocrinol 2010; 31: 79-84.
21. Pirker S, Czech T, Baumgartner C, Maier H, Novak K, Fürtinger S, Fischer-Colbrie R, Sperk G. Chromogranins as markers of altered hippocampal circuitry in temporal lobe epilepsy. Ann Neurol 2001; 50: 216-226.
22. Lechner T, Adlassnig C, Humpel C, Kaufmann WA, Maier H, Reinstadler-Kramer K, Hinterhölzl J, Mahata SK, Jellinger KA, Marksteiner J. Chromogranin peptides in Alzheimer's disease. Exp Gerontol 2004; 39: 101-113.
23. Synder SE, Peng B, Pintar JE, Salton SR. Expression of VGF mRNA in developing neuroendocrine and endocrine tissues. J Endocrinol 2003; 179: 227-235.
24. Hahm S, Mizuno TM, Wu TJ, Wisor JP, Priest CA, Kozak CA, Boozer CN, Peng B, McEvoy RC, Good P, Kelley KA, Takahashi JS, Pintar JE, Roberts JL, Mobbs CV, Salton SR. Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron 1999; 23: 537-548.
25. Hahm S, Frekete C, Mizuno TM, Windsor J, Yan H, Boozer CN, Lee C, Elmquist JK, Lechan RM, Mobbs CV, Salton SR. VGF is required for obesity induced by diet, gold thioglucose treatment and agouti, and is differentially regulated in POMC- and NPY- containing arcuate neurons in response to fasting. J Neurosci 2002; 22: 6929-6938.
26. Wei S, Feng Y, Che FY, Pan H, Mzhavia N, Devi LA, McKinzie AA, Levin N, Richards WG, Fricker LD. Obesity and diabetes in transgenic mice expressing proSAAS. J Endocrinol 2004; 180: 357-368.
27. Che FY, Yuan Q, Kalinina E, Fricker LD. Peptidomics of Cpe fat/fat mouse hypothalamus: effect of food deprivation and exercise on peptide levels. J Biol Chem 2005; 280: 4451-4461.
28. Horvath TL. Synaptic plasticity in energy balance regulation. Obesity (Silver Spring) 2006; 14: 228S-233S.
29. Boucher J, Quilliot D, Pradères JP, Simon MF, Grès S, Guigné C, Prévot D, Ferry G, Boutin JA, Carpéné C, Valet P, Saulnier-Blache JS. Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 2005; 48: 569-577.
30. Schmidt CJ, Jubier MF, Hamer DH. Structure and expression of two human metallothionein-I isoform genes and a related pseudogene. J Biol Chem 1985; 260: 7731-7737.
31. Penkowa M, Florit S, Giralt M, Quintana A, Molinero A, Carrasco J, Hidalgo J. Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures. J Neurosci Res 2005; 79: 522-534.
32. Wakida K, Shimazawa M, Hozumi I, Satoh M, Nagase H, Inuzuka T, Hara H. Neuroprotective effect of erythropoietin, and role of metallothionein-1 and -2, in permanent focal cerebral ischemia. Neuroscience 2007; 148: 105-114.
33. Beattie JH, Wood AM, Newman AM, Bremner I, Choo KH, Michalska AE, Duncan JS, Trayhurn P. Obesity and hyperleptinemia in metallothionein (-I and -II) null mice. Proc Natl Acad Sci USA 1998; 95: 358-363.
34. Do MS, Nam SY, Hong SE, Kim KW, Duncan JS, Beattie JH, Trayhurn P. Metallothionein gene expression in human adipose tissue from lean and obese subjects. Horm Metab Res 2002; 34: 348-351.
35. Wang B, Wood IS, Trayhurn P. PCR arrays identify metallothionein-3 as a highly hypoxia-inducible gene in human adipocytes. Biochem Biophys Res Commun 2008; 368: 88-93.
36. Urade Y, Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 2000; 1482: 259-271.
37. Jordan W, Tumani H, Cohrs S, Eggert S, Rodenbeck A, Brunner E, Rüther E, Hajak G. Prostaglandin D synthase (beta-trace) in healthy human sleep. Sleep 2004; 27: 867-874.
38. Barceló A, de la Peña M, Barbé F, Pierola J, Bosch M, Agustí AG. Prostaglandin D synthase (beta trace) levels in sleep apnea patients with and without sleepiness. Sleep Med 2007; 8: 509-511.
39. Gjerris A, Gjerris F, Sorensen PS, Christensen NJ, Fahrenkrug J, Rehfeld JF. Do concentrations of neurotransmitters measured in lumbar CSF reflect the concentrations at brain level? Acta Neurochir (Wien) 1988; 91: 55-59.
40. Moir AT, Ashcroft GW, Crawford TB, Eccleston D, Guldberg HC. Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain 1970; 93: 357-368.